FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039278049> ?p ?o ?g. }

• W2039278049 endingPage "3774" @default.
• W2039278049 startingPage "3765" @default.
• W2039278049 abstract "Abstract Interactions between the proteasome inhibitor bortezomib and histone deacetylase inhibitors (HDIs) have been examined in Bcr/Abl+ human leukemia cells (K562 and LAMA 84). Coexposure of cells (24-48 hours) to minimally toxic concentrations of bortezomib + either suberoylanilide hydroxamic acid (SAHA) or sodium butyrate (SB) resulted in a striking increase in mitochondrial injury, caspase activation, and apoptosis, reflected by caspases-3 and -8 cleavage and poly(adenosine diphosphate-ribose) polymerase (PARP) degradation. These events were accompanied by down-regulation of the Raf-1/mitogen-induced extracellular kinase (MEK)/extracellular signal-related kinase (ERK) pathway as well as diminished expression of Bcr/Abl and cyclin D1, cleavage of p21CIP1 and phosphorylation of the retinoblastoma protein (pRb), and induction of the stress-related kinases Jun kinase (JNK) and p38 mitogen-activated protein kinase (MAPK). Transient transfection of cells with a constitutively active MEK construct significantly protected them from bortezomib/SAHA-mediated lethality. Coadministration of bortezomib and SAHA resulted in increased reactive oxygen species (ROS) generation and diminished nuclear factor κB (NF-κB) activation; moreover, the free radical scavenger L-N-acetylcyteine (LNAC) blocked bortezomib/SAHA-related ROS generation, induction of JNK and p21CIP1, and apoptosis. Lastly, this regimen potently induced apoptosis in STI571 (imatinib mesylate)-resistant K562 cells and CD34+ mononuclear cells obtained from a patient with STI571-resistant disease, as well as in Bcr/Abl- leukemia cells (eg, HL-60, U937, Jurkat). Together, these findings raise the possibility that combined proteasome/histone deacetylase inhibition may represent a novel strategy in leukemia, including apoptosis-resistant Bcr/Abl+ hematologic malignancies. (Blood. 2003;102:3765-3774)" @default.
• W2039278049 created "2016-06-24" @default.
• W2039278049 creator A5014658692 @default.
• W2039278049 creator A5015735013 @default.
• W2039278049 creator A5049658773 @default.
• W2039278049 creator A5061036144 @default.
• W2039278049 creator A5065920653 @default.
• W2039278049 creator A5069980003 @default.
• W2039278049 date "2003-11-15" @default.
• W2039278049 modified "2023-09-30" @default.
• W2039278049 title "The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571" @default.
• W2039278049 cites W161377905 @default.
• W2039278049 cites W1970001436 @default.
• W2039278049 cites W1973899902 @default.
• W2039278049 cites W1974090542 @default.
• W2039278049 cites W1976385326 @default.
• W2039278049 cites W1979104079 @default.
• W2039278049 cites W1993353592 @default.
• W2039278049 cites W2002807315 @default.
• W2039278049 cites W2006917576 @default.
• W2039278049 cites W2008431663 @default.
• W2039278049 cites W2010268104 @default.
• W2039278049 cites W2012968783 @default.
• W2039278049 cites W2015616444 @default.
• W2039278049 cites W2022285476 @default.
• W2039278049 cites W2024859791 @default.
• W2039278049 cites W2034420402 @default.
• W2039278049 cites W2048364301 @default.
• W2039278049 cites W2057942504 @default.
• W2039278049 cites W2066441195 @default.
• W2039278049 cites W2067530043 @default.
• W2039278049 cites W2077945404 @default.
• W2039278049 cites W2085307511 @default.
• W2039278049 cites W2091735622 @default.
• W2039278049 cites W2094830334 @default.
• W2039278049 cites W2108230631 @default.
• W2039278049 cites W2120590293 @default.
• W2039278049 cites W2123339281 @default.
• W2039278049 cites W2123408027 @default.
• W2039278049 cites W2123513769 @default.
• W2039278049 cites W2133468132 @default.
• W2039278049 cites W2146965545 @default.
• W2039278049 cites W2157438849 @default.
• W2039278049 cites W2163104842 @default.
• W2039278049 cites W2171483351 @default.
• W2039278049 cites W2204123985 @default.
• W2039278049 cites W2318668978 @default.
• W2039278049 cites W2324841416 @default.
• W2039278049 cites W2329648702 @default.
• W2039278049 cites W2331087852 @default.
• W2039278049 cites W3113125785 @default.
• W2039278049 cites W4244921051 @default.
• W2039278049 doi "https://doi.org/10.1182/blood-2003-03-0737" @default.
• W2039278049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12893773" @default.
• W2039278049 hasPublicationYear "2003" @default.
• W2039278049 type Work @default.
• W2039278049 sameAs 2039278049 @default.
• W2039278049 citedByCount "259" @default.
• W2039278049 countsByYear W20392780492012 @default.
• W2039278049 countsByYear W20392780492013 @default.
• W2039278049 countsByYear W20392780492014 @default.
• W2039278049 countsByYear W20392780492015 @default.
• W2039278049 countsByYear W20392780492016 @default.
• W2039278049 countsByYear W20392780492017 @default.
• W2039278049 countsByYear W20392780492018 @default.
• W2039278049 countsByYear W20392780492019 @default.
• W2039278049 countsByYear W20392780492021 @default.
• W2039278049 countsByYear W20392780492023 @default.
• W2039278049 crossrefType "journal-article" @default.
• W2039278049 hasAuthorship W2039278049A5014658692 @default.
• W2039278049 hasAuthorship W2039278049A5015735013 @default.
• W2039278049 hasAuthorship W2039278049A5049658773 @default.
• W2039278049 hasAuthorship W2039278049A5061036144 @default.
• W2039278049 hasAuthorship W2039278049A5065920653 @default.
• W2039278049 hasAuthorship W2039278049A5069980003 @default.
• W2039278049 hasConcept C104317684 @default.
• W2039278049 hasConcept C153911025 @default.
• W2039278049 hasConcept C171122931 @default.
• W2039278049 hasConcept C184235292 @default.
• W2039278049 hasConcept C185592680 @default.
• W2039278049 hasConcept C190283241 @default.
• W2039278049 hasConcept C203014093 @default.
• W2039278049 hasConcept C2776364478 @default.
• W2039278049 hasConcept C2777478702 @default.
• W2039278049 hasConcept C2777583451 @default.
• W2039278049 hasConcept C2778305200 @default.
• W2039278049 hasConcept C2778367456 @default.
• W2039278049 hasConcept C2778729363 @default.
• W2039278049 hasConcept C2778942008 @default.
• W2039278049 hasConcept C3019892230 @default.
• W2039278049 hasConcept C502942594 @default.
• W2039278049 hasConcept C55493867 @default.
• W2039278049 hasConcept C57074206 @default.
• W2039278049 hasConcept C64927066 @default.
• W2039278049 hasConcept C86803240 @default.
• W2039278049 hasConcept C95444343 @default.
• W2039278049 hasConceptScore W2039278049C104317684 @default.
• W2039278049 hasConceptScore W2039278049C153911025 @default.

• next